Angel Baldán

Summary

Affiliation: Saint Louis University
Country: USA

Publications

  1. pmc miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity
    Ryan M Allen
    Edward A Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, MO, USA
    EMBO Mol Med 4:882-95. 2012
  2. pmc Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice
    Tyler J Marquart
    Edward A Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA
    Arterioscler Thromb Vasc Biol 33:455-8. 2013

Collaborators

  • Tyler J Marquart
  • Ryan M Allen
  • Aldons J Lusis
  • Judy Wu
  • Frederick J Suchy
  • Meenakshisundaram Ananthanarayanan
  • Carolyn J Albert
  • David Q H Wang
  • David A Ford

Detail Information

Publications2

  1. pmc miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity
    Ryan M Allen
    Edward A Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, MO, USA
    EMBO Mol Med 4:882-95. 2012
    ..Importantly, pretreatment of mice with anti-miR-33 oligonucleotides rescues the hepatotoxic phenotype. Therefore, we conclude that miR-33 mediates some of the undesired, hepatotoxic effects of statins...
  2. pmc Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice
    Tyler J Marquart
    Edward A Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA
    Arterioscler Thromb Vasc Biol 33:455-8. 2013
    ..To determine the efficacy of long-term anti-miR-33 therapy on the progression of atherosclerosis in high-fat, high-cholesterol-fed Ldlr(-/-) mice...